Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study

Table 4 Statin type and the risk of pneumonia requiring hospitalization within a 90-day exposure

	Controls	Cases	Crude OR		Adjusted^a OR
	N	N	(95 % CI)	P	(95 % CI)	P
Overall MI patients	4,778	963	-		-
Statin type
Artovastatin	3,242	639	1.00 (Ref.)		1.00 (Ref.)
Fluvastatin	556	132	1.21 (0.94–1.56)	0.136	1.14 (0.85–1.52)	0.390
Simvastatin	510	109	1.04 (0.79–1.38)	0.781	1.19 (0.87–1.64)	0.283
Other	470	83	0.87 (0.65–1.17)	0.363	0.73 (0.51–1.03)	0.075
MI patients unexposed to statin pretreatment	2,683	403
Statin type
Atorvastatin	1,863	270	1.00 (Ref.)		1.00 (Ref.)
Fluvastatin	297	55	1.16 (0.71–1.90)	0.549	1.11 (0.6–2.04)	0.743
Simvastatin	278	54	0.80 (0.49–1.32)	0.386	1.12 (0.59–2.10)	0.729
Other	245	24	0.65 (0.36–1.17)	0.153	0.66 (0.31–1.41)	0.286

ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS ₂ congestive heart failure, hypertension, age > 75 years, diabetes, previous stroke, CI confidence interval; COPD, chronic obstructive pulmonary disease, DDD defined daily dose, DDD ₉₀ average defined daily dose within 90 days, OR odds ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
^a Adjusted for CHASD₂ score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease, Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate, antiplatelet and influenza or pneumococcal vaccine)

ISSN: 1471-2261